Nature’s endless wonder: unexpected motherhood after pediatric allogeneic stem cell transplantation and severe late effects

Dorothea Bauer · Raffaela Tüchler · Daniela Dörfler · Anita Lawitschka

Received: 22 June 2019 / Accepted: 17 March 2020 / Published online: 7 April 2020
© The Author(s) 2020

Summary Infertility and endocrine late effects (LE) are common sequelae after pediatric allogeneic hematopoietic stem cell transplantation (HSCT) after myeloablative conditioning. Nevertheless, the individual risk for these LE is not always easy to predict and therefore these issues are of ongoing interest to the clinical research community dealing with HSCT aftercare. This article describes the case of a young woman who received polychemotherapy and total body irradiation (TBI) containing conditioning for HSCT for a relapsed anaplastic large cell lymphoma (ALCL). She developed severe sclerotic chronic graft-versus-host disease (GVHD) with irreversible joint contractures and multiorgan involvement, requiring long-term multimodal immunosuppressive treatment. Subsequently showing a considerable number of LE including hypergonadotrophic hypogonadism, she accepted that infertility would be quite likely. Her courageous personal life planning included part-time working and a partnership but not motherhood. This article reports the unexpected and spontaneous pregnancy and the extreme preterm birth of a surprisingly adequately developing child.

Keywords Fertility · Pregnancy · Late effects · Hypogonadism · Chronic graft versus host disease

Introduction

Gonadal dysfunction and infertility are common late effects (LE) after pediatric allogenic hematopoietic stem cell transplantation (HSCT) in females [1]. The incidence of endocrine LE is reported to be higher in chronic graft-versus-host disease (cGVHD) patients, mainly due to long-term immunosuppressive therapy [2]. Since the production of germ cells is completed in the postnatal ovary, follicular depletion caused by adverse effects of cancer treatment or conditioning therapy may be definite [3]. This can result in ovarian failure or in early onset of menopause [4].

The risk of developing gonadal failure is decisively influenced by the pubertal stage at HSCT (before or after onset of puberty) and by the conditioning regimen [5]. Although the ovaries of prepubertal children and adolescents are relatively resistant to chemotherapy-induced damage compared to the ones of adults, alkylating agents such as cyclophosphamide (CY) or high-dose busulfan (BU) are considered to impair gonadal function even in very young patients [1, 6]. Total body irradiation (TBI) as conditioning for HSCT shows the greatest risk of evoking acute ovarian failure. Among girls being treated with fractionated TBI, prepubertal girls are more likely to maintain ovarian function, [7] but still 50% of girls being aged under 10 years at the time of transplantation will suffer acute loss of ovarian function [8]. Ovarian dysfunction, especially when observed early after HSCT, may be transient [9]. Persistent hypergonadotrophic hypogonadism during long-term follow-up, however, is often an indication of permanent ovarian failure. Nonetheless, rare cases of spontaneous recovery of ovarian function many years after onset have been reported [10].
If pregnancies occur in patients after HSCT, they are likely to have a successful outcome; however, they carry higher risks for spontaneous abortions and miscarriages, preterm delivery and low birth weight. Thus, these pregnancies should be treated as high risk for maternal and fetal complications [11].

Case presentation

The patient, born in March 1993, was diagnosed with an anaplastic large cell lymphoma (ALCL) in October 2002 and received polychemotherapy according to the international ALCL 99 protocol: standard risk arm (cytarabine, ifosfamide, methotrexate, etoposide, doxorubicin) [12], resulting in complete remission. When a relapse occurred in January 2003 polychemotherapy according to NHL-BFM 95 was initiated [13]. After three cycles of chemotherapy (including vindesine, cytarabine, etoposide, methotrexate and ifosfamide) tumor progression was diagnosed in March 2003 but luckily after treatment intensification with vincristine, cyclophosphamide, methotrexate, doxorubicin, vindesine, cytarabine and etoposide tumor regression could be achieved. The indications for an allogenic HSCT to ensure long-term cure were confirmed. The myeloablative conditioning consisted of fractionated TBI (12Gy), etoposide and cyclophosphamide. As GVHD prophylaxis methotrexate (MTX) and cyclosporin A (CSA) were administered. The HSCT with bone marrow of a matched family donor was performed in May 2003 and the patient has been in remission since; however, she developed extensive multisystemic sclerotic cGVHD including scleroderma, joint contractures, keratoconjunctivitis sicca, xerostomia, vulvovaginitis, chest wall sclerosis with a combined ventilation disorder, which made a multimodal immunosuppressive treatment in several treatment lines over 6 years necessary. Subsequently, she developed malabsorption and cachexia, a reactive depressive disorder and osteoporosis, which complicated her long-lasting time of rehabilitation and psychosocial reintegration. Finally, immunosuppressive treatment could be tapered and stopped in 2009, leaving partial scleroderma and joint contractures with reduced range of motion as irreversible but inactive GVHD sequelae. Movement in all joints was reduced, especially in both wrist joints, where no flexion, hardly any extension and no rotation were possible. Most movements in the fingers were limited. Movement in the hips (abduction/adduction right: 30°-0°-40°, left: 30°-0°-20°) and knees (extension/extension right and left: 10°-0°-135°) were partially reduced (Fig. 1).

In 2007 she was diagnosed with delayed puberty connected with primary amenorrhea and hypergonadotropic hypogonadism. Hormonal replacement therapy (HRT) with estrogen for puberty induction was slowly initiated and increased to adult dosing over 2 years. When breakthrough bleeding occurred, progesterone was added based on the clinical practice guidelines for the care of girls and women with Turner syndrome [14]. Hormone levels were frequently checked with no substantial change for 7 years. In 2010 HRT withdrawal was tried for 3 months, still showing reduced gonadal function. After successful pubertal development, HRT was switched to a combination of progesterin and estradiol in 2013. In 2015 HRT was discontinued at low follicle stimulating hormone (FSH) and luteotropic hormone (LH) levels and 6 months later (beginning of year 2016, at the age of 22 years) the patient reported a normal menstrual cycle for the first time in her life. She reported regular bleeding until December 2016. Antimüllerian hormone (AMH) was not detectable (<0.08 ng/ml, Table 1).

According to international guidelines, the patient was cared for in the St. Anna HSCT outpatient and LE clinic by an interdisciplinary team including rehabilitation stays, regular psychological and physiotherapeutic care, professional and nutritional counselling, social work and occupational therapy [2, 15]. She was able to complete an apprenticeship as an office administrator and then worked part-time.

On January 2017, at the age of 23 years, the unexpected pregnancy at an estimated 19+4 weeks
Table 1  Hormone levels in the patient before and after pregnancy

| Hormone                      | Before pregnancy⁹ | After pregnancy⁹ | Reference range | Unit |
|------------------------------|-------------------|------------------|-----------------|------|
| Luteotropic hormone          | 2.6               | 4.7              | 2.4–95.6        | mlU/mL |
| Follicle stimulating hormone | 4.5               | 5.6              | 1.7–21.5        | mlU/mL |
| 17-beta estradiol            | ≤5                | 89               | 26.7–314        | pg/mL |
| Parathyroid hormone          | 24.1              | 25.5             | 15–65           | pg/mL |
| 25-hydroxy-vitamin D         | 109.0             | 44.9             | 75–250          | nmol/L |
| Osteocalcin                  | 21.0              | 21.4             | 11–36           | ng/mL |
| Antimüllerian hormone        | <0.08             | 0.10             | 0.89–9.85       | ng/mL |

⁹ 2015/2016

The latest hormone status in May 2018 is summarized in Table 1. Postpartum, the patient returned to a regular menstrual cycle and does not need any HRT. She reports a satisfactory sexual life and no problems concerning continence. Particularly striking is the AMH level of 0.1 ng/ml which has risen compared to the last value before the pregnancy.

Discussion

The present case history is sensational in several aspects: firstly, recovery of ovarian function and thus spontaneous conception is extremely rare in female childhood cancer survivors having been diagnosed with hypogonadism for several years [16, 17].

Rare cases of unexpected recovery of ovarian function many years after HSCT (and in some cases after TBI-based conditioning regimens) have been published, however, none of them reporting pregnancy [10, 18].

Borgmann-Staudt et al. investigated the long-term fertility outcome of 344 patients after pediatric HSCT. Successful pregnancies were reported in three females, none of them having received TBI [19]. Details on the hormone status of these patients after HSCT were not given in this study; however, the median follow-up was 6 years, indicating shorter intervals of hypogonadism as in the present case.

It is not only surprising that the patient became pregnant after having been diagnosed with hypogonadism for 7 years, but also that she showed non-detectable AMH levels (<0.08 ng/ml) at the last check-up before pregnancy. In the general population, this would not only be considered to be too low to conceive spontaneously, but is also far below the established cut-off value of 1.4 ng/ml to predict an ongoing pregnancy after assisted reproduction [20]. Several studies showed decreased AMH levels among female survivors of childhood cancer. Especially in patients reporting normal menses, AMH measurement may be a useful tool to search for subfertility [21]. Among those having received three or more cycles of polychemotherapy or TBI, AMH levels are reported to be the lowest which both polychemotherapy and TBI applies to our patient; however, for female patients with a history of pediatric HSCT and pathologic AMH val-
ues, the correlation between especially low values and fewer pregnancy rates has not been described so far.

Of further research interest would be the long-term evaluation of AMH serum levels after pediatric HSCT. In the present case, AMH levels increased 15 years after HSCT at the age of 25 years from undetectable values to 0.1 ng/ml. Miyoshi et al. published 2016 observations on AMH levels in three girls after cancer treatment: two of them received HSCT; in one patient AMH levels became undetectable during follow-up and in the other AMH levels recovered only transiently; however, follow-up was only 36 months in this study [22].

A prospective pilot study was recently conducted at the SCT aftercare clinic of the St. Anna Children’s Hospital in cooperation with the Outpatient Clinic for children and adolescent gynecology of the University Clinic for Gynecology Vienna on gynecologic aftercare and the human papilloma virus status of females aged 12–22 years (submitted). Hypogonadism was observed in 67% (12/18) of the patients and pathologic AMH levels in 94% (17/18).

Secondly, female survivors of childhood cancer are less likely to have a live birth than healthy siblings [23].

Belashov et al. published in 2011 a case report about a pregnancy in a patient after multiple courses of high-dose chemotherapy and BU-based myeloablative conditioning for HSCT. Ovarian recovery occurred already 1 year after HSCT and the pregnancy ended in an abortion at 11 weeks gestational age.

In the present case, risk factors for the progress of the pregnancy included not only the history of multiple courses of high-dose polychemotherapy, TBI and HSCT, but also the development of an extensive multisystemic sclerotic cGVHD including chest and abdominal wall sclerosis requiring long-term multimodal immunosuppressive treatment. For patients with scleroderma, higher risks of pre-eclampsia, premature delivery and small full-term infants are reported [24]. In the placentas, severe fibrosis and premature delivery and small full-term infants are reported with scleroderma, higher risks of pre-eclampsia, premature delivery and small full-term infants are reported in three girls after cancer treatment: two of them received HSCT; in one patient AMH levels became undetectable during follow-up and in the other AMH levels recovered only transiently; however, follow-up was only 36 months in this study [22].

Thirdly, nearly 40% of infants born at 24 weeks gestational age do not survive and another 40% show severe neurodevelopmental impairment [26]. Thus, also the favorable outcome of the child is considered to be extraordinary. Due to the late diagnosis of pregnancy it appears that the child was small for gestational age and older than expected. This would also explain the favorable outcome.

Conclusion
To our knowledge this is the first published case of ovarian function restoration, spontaneous pregnancy and birth of a ultimately adequately developed child in a female patient having been diagnosed with hypogonadism for 7 years after multiple courses of high-dose poly-chemotherapy, TBI-based myeloablative conditioning for pediatric HSCT followed by severe sclerotic cGVHD and multiple LE.

This case proves that recovery of ovarian function is possible even many years after the onset of primary ovarian failure and it illustrates the complexity of diagnosis and outcome prediction of ovarian malfunction and infertility after pediatric HSCT.

Funding Open access funding provided by Medical University of Vienna.

Compliance with ethical guidelines
Conflict of interest D. Bauer, R. Tüchler, D. Dörfler and A. Lawitschka declare that they have no competing interests.

Ethical standards Informed consent was obtained from all individual participants for whom information is included in this article.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References
1. Dvorak CC, et al. NCI, NHLBI/PBMTC first international conference on late effects after pediatric hematopoietic cell transplantation: endocrine challenges—thyroid dysfunction, growth impairment, bone health, & reproductive risks. Biol Blood Marrow Transplant. 2011;17(12):1725–38.
2. Hilgendorf I, Greinix H, Halter JP, Lawitschka A, Bertz H, Wolff D. Long-term follow-up after allogeneic stem cell transplantation. DischArzteblInt. 2015;112(4):51–8.
3. Johnson J, Canning J, Kaneko T, Pru JK, Tilly JL. Germline stem cells and follicular renewal in the postnatal mammalian ovary. Nature. 2004;428(6979):145–50.
4. Faddy MJ, Gosden RG, Gougeon A, Richardson SJ, Nelson JE. Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause. Hum Reprod. 1992;7(10):1342–6.
5. Shalet SM. Effects of cancer chemotherapy on gonadal function of patients. Cancer Treat Rev. 1980;7(3):141–52.
6. Sklar C. Maintenance of ovarian function and risk of premature menopause related to cancer treatment. J Natl Cancer Inst Monogr. 2005;34:25–7.

7. Roziajkova L, Mladosievicova B. Endocrine late effects after hematopoietic stem cell transplantation. Oncol Res. 2010;18(11–12):607–15.

8. Sklar C. Growth and endocrine disturbances after bone marrow transplantation in childhood. Acta Paediatr Suppl. 1995;411:57–61. discussion:62.

9. Papadakis V, et al. Gonadal function in young patients successfully treated for Hodgkin disease. Med Pediatr Oncol. 1999;32(5):366–72.

10. Rahhal SN, Eugster EA. Unexpected recovery of ovarian function many years after bone marrow transplantation. J Pediatr. 2008;152(2):289–90.

11. Salooja N, et al. Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective survey. Lancet. 2018;358(9278):271–6.

12. Brugieres L, et al. Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group. J Clin Oncol. 2009;27(6):897–903.

13. Woessmann W, et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood. 2005;105(3):948–58.

14. Gravholt CH, et al. Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. Eur J Endocrinol. 2017;177(3):G1–G70.

15. Lawitschka A, Peters C. Long-term effects of myeloablative allogeneic hematopoietic stem cell transplantation in pediatric patients with acute lymphoblastic leukemia. Curr Oncol Rep. 2018;20(9):74.

16. Miyoshi Y, et al. Endocrinological analysis of 122 Japanese childhood cancer survivors in a single hospital. Endocr J. 2008;55(6):1055–63.

17. Sanders JE, et al. Ovarian function following marrow transplantation for aplastic anemia or leukemia. J Clin Oncol. 1988;6(5):813–8.

18. Sarafoglou K, Boulad F, Gillio A, Sklar C. Gonadal function after bone marrow transplantation for acute leukemia during childhood. J Pediatr. 1997;130(2):210–6.

19. Borgmann-Staudt A, et al. Fertility after allogeneic haematopoietic stem cell transplantation in childhood and adolescence. Bone Marrow Transplant. 2012;47(2):271–6.

20. Lie Fong S, et al. Assessment of ovarian reserve in adult childhood cancer survivors using anti-Mullerian hormone. Hum Reprod. 2009;24(4):982–90.

21. Charpentier A-M, et al. Anti-Mullerian hormone screening to assess ovarian reserve among female survivors of childhood cancer. J Cancer. 2014;8(4):546–54.

22. Miyoshi Y, et al. Longitudinal observation of serum anti-Mullerian hormone in three girls after cancer treatment. Clin Pediatr Endocrinol. 2016;25(4):119–26.

23. Green DM, et al. Pregnancy outcome of female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Am J Obstet Gynecol. 2002;187(4):1070–80.

24. Kamper-Jorgensen M, Gammill HS, Nelson JL. Preeclampsia and scleroderma: a prospective nationwide analysis. Acta Obstet Gynecol Scand. 2018;97(5):587–90.

25. Ibba-Manneschi L, et al. Severe fibrotic changes and altered expression of angiogenic factors in maternal scleroderma: placental findings. Ann Rheum Dis. 2010;69(2):458–61.

26. Glass HC, Costarino AT, Stayer SA, Brett CM, Cladis F, Davis PJ. Outcomes for extremely premature infants. Anesth Analg. 2015;120(6):1337–51.

**Publisher’s Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.